IRIDEX Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRIX research report →
Range $2.75 – $2.75
Price Chart
About the company
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions.
- CEO
- Patrick Mercer
- IPO
- 1996
- Employees
- 93
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on IRIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.92M
- P/E
- -2.30
- Fwd P/E
- 6.36
- PEG
- -0.05
- P/S
- 0.16
- P/B
- 2.98
- EV/EBITDA
- -6.88
- Div Yield
- 0.00%
- Gross Margin
- 38.53%
- Op Margin
- -5.14%
- Net Margin
- -6.85%
- ROE
- -84.80%
- ROIC
- -15.50%
Latest fiscal year · YoY change
- Revenue
- $52.67M+8.2%
- Gross Profit
- $19.31M-1.0%
- Op Income
- $-2,571,000
- Net Income
- $-4,437,000+50.2%
- EPS
- $-0.26+51.9%
- OCF Growth
- +71.0%
- FCF Growth
- +69.1%
- 52W High
- $1.65
- 52W Low
- $0.43
- 50D MA
- $0.70
- 200D MA
- $0.98
- Beta
- 0.67
- RSI (14)
- 25
- Avg Volume
- 385.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IRIDEX posted weaker-than-expected Q3 revenue, but gross margin improved sharply and management is positioning the company for better profitability in 2027 through cost cuts, manufacturing relocation, and product-mix changes.· November 17, 2026
- Q3 revenue was $10.2 million, down from $12.5 million a year ago, as international retina and probe orders softened.
- Gross margin improved to 42.4% from 32.1% year over year; excluding a prior-year $0.8 million inventory write-down, pro forma margin was 38.7%.
- Net loss was $1.4 million, or $0.08 per share, versus a $1.6 million loss, or $0.09 per share, last year.
- IRIDEX raised full-year 2026 revenue guidance to $46 million-$48 million, still excluding Middle East revenue.
- Management said Q4 should benefit from safety-stock conversion, deferred Japan shipments, and seasonal strength, but retina headwinds remain.
- The company completed its San Jose manufacturing move and expects about $600,000 of annualized rent savings, with more margin benefits to come in 2027.
Third-quarter 2026 revenue was $10.2 million, down from $12.5 million in the third quarter of 2025. Retina product revenue was $5.1 million versus $6.7 million a year ago; Cyclo G6 product family revenue was $3.2 million versus $3.5 million; and other revenue was $1.9 million versus $2.2 million. Gross profit was $4.3 million and gross margin was 42.4%, compared with $4.0 million and 32.1% a year ago; excluding a prior-year one-time $0.8 million inventory write-down, gross margin would have been 38.7%, up about 370 basis points year over year. Net loss was $1.4 million, or $0.08 per share, versus $1.6 million, or $0.09 per share, last year; adjusted EBITDA was a loss of $0.6 million versus a loss of $0.1 million. Cash and cash equivalents ended at $3.7 million, down from $4.7 million at the end of Q2, and operating cash use was $1.0 million. Full-year 2026 revenue guidance was raised to $46 million-$48 million, and adjusted operating expenses are still expected to be $19 million-$19.5 million. Management did not provide 2027 guidance, but said it expects 2027 to reflect lower costs, higher gross margin from contract manufacturing, and a more profitable business mix.
Patrick Mercer said the quarter showed important structural progress, especially the completion of the manufacturing move to San Jose and a meaningful step-up in gross margin. He said the company is focused on positioning IRIDEX for greater profitability in 2027 through lower rent, better manufacturing economics, and a strategic review of the product portfolio and distribution model. His tone was candid about the quarter being disappointing, but confident that the company is moving toward a more efficient and cash-generative operating model.
Romeo Dizon detailed the financial impact of the weaker quarter, including $10.2 million in revenue, a 42.4% gross margin, a $1.4 million net loss, and $1.0 million of operating cash use. He attributed the cash burn mainly to a $1.6 million increase in inventory tied to safety stock for international blackout periods and lower revenue, and said cash utilization should decline as inventory converts back to revenue. He reiterated full-year 2026 guidance of $46 million-$48 million in revenue and $19 million-$19.5 million in adjusted operating expenses, while saying 2027 should benefit from the relocation, operating expense reductions, and contract manufacturing.
Analysts focused on the sharp decline in retina and asked whether IRIDEX is losing share, especially in China, Japan, and Europe. Management said China was particularly weak, Japan orders were volatile because distributors stocked ahead of the relocation, and European delay was tied to distributors waiting for MDR approval of the newer PASCAL IP product; Patrick said the company is still selling existing PASCAL there but some buyers are waiting for the new version. Questions also covered G6 probe and system trends, where management said Q4 is typically the strongest quarter and expects both probes and systems to increase sequentially and year over year. On profitability, Romeo said Q4 could be adjusted EBITDA positive if revenue lands at the high end of the quarter’s range, but not for the full year because of earlier losses.
The company did improve gross margin materially, and management framed the San Jose move and the shift to third-party contract manufacturing as the start of a larger margin expansion cycle. Glaucoma appears to be a bright spot, with U.S. G6 probe volume holding up, U.S. system placements improving, and management citing favorable reimbursement and stronger clinical evidence. Management also expects safety-stock conversion, deferred Japan shipments, and seasonal Q4 strength to support near-term results.
Revenue missed expectations, and management pointed to multiple ongoing headwinds in retina: weak China demand, Japan shipment timing, European regulatory delays, and competitive pricing pressure. Cash declined to $3.7 million and operating cash use was $1.0 million, showing the business is still consuming cash despite margin improvement. Management also said the Middle East is excluded from guidance and is not expected to recover in the near-term outlook, while 2027 benefits depend on execution across manufacturing, regulation, and portfolio rationalization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.2%
- Shares Outstanding
- 17.81M
- Float Shares
- 10.89M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.00M | 0 |
| Vanguard Group Inc | 578.71K | 0 |
| Vanguard Capital Management LLC | 514.59K | 0 |
| Renaissance Technologies LLC | 333.26K | ▼ 90.28K |
| Morgan Stanley | 305.19K | 0 |
| Geode Capital Management, LLC | 138.96K | 0 |
| Citadel Advisors LLC | 98.95K | ▲ 38.10K |
| Vanguard Fiduciary Trust Co | 60.16K | 0 |
| State Street Corp | 44.72K | 0 |
| Perkins Capital Management Inc | 41.05K | ▼ 29.75K |
| Goldman Sachs Group Inc | 40.45K | ▲ 2.83K |
| United Capital Financial Advisors, LLC | 29.53K | ▼ 6.00K |
Held by 20 ETFs
Biggest fund positions in IRIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Novel Inspiration International Co., Ltd. | other | 146,313 |
| Mar 30, 26 | Lin Shih-Yao David | buy | 7,371 |
| Mar 24, 26 | Lin Shih-Yao David | buy | 4,549 |
| Mar 23, 26 | Lin Shih-Yao David | buy | 17,526 |
| Mar 17, 26 | Lin Shih-Yao David | buy | 22,805 |
| Mar 16, 26 | Lin Shih-Yao David | buy | 1,682 |
| Mar 12, 26 | Lin Shih-Yao David | buy | 967 |
| Mar 3, 26 | Lin Shih-Yao David | buy | 752 |
| Mar 2, 26 | Lin Shih-Yao David | buy | 1,424 |
| Feb 23, 26 | Lin Shih-Yao David | buy | 14,943 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRIX coverage
Recent articles, reports, and earnings notes.
No research on IRIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRIX report →IRIDEX Q3 Earnings Call Highlights
defenseworld.net · Nov 19
IRIDEX Corporation (IRIX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 17
Iridex Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 17
Contrasting IRIDEX (NASDAQ:IRIX) and Medtronic (NYSE:MDT)
defenseworld.net · Nov 17
Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026
globenewswire.com · Nov 3
IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 10,000 Shares
defenseworld.net · Oct 7
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
globenewswire.com · Oct 5
IRIDEX (NASDAQ:IRIX) Shares Cross Below 200-Day Moving Average – Here’s Why
defenseworld.net · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.